Doxylamine

CHEMBL1004 Phase 4 Aprovado Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
270.4 g/mol
LogP
2.5
Phase
4

An antihistamine with sedating properties used to treat insomnia and, in combination with pyridoxine, to treat nausea and vomiting during pregnancy. It works by blocking histamine receptors in the brain.

Peso Molecular

270,3700 g/mol

LogP

2,50

TPSA

25,40 Ų

Regra dos 5 de Lipinski

Aprovado

Áreas Terapêuticas

Mecanismo de Ação

Competitively blocks histamine H1 receptors on effector cells, preventing histamine-mediated vasodilation, increased vascular permeability, bronchoconstriction, and pruritus. First-generation agents also cross the blood-brain barrier, causing sedation.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

Competitively blocks histamine H1 receptors on effector cells, preventing histamine-mediated vasodilation, increased vascular permeability, bronchoconstriction, and pruritus. First-generation agents also cross the blood-brain barrier, causing sedation.

Estrutura 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CN(C)CCOC(C)(c1ccccc1)c1ccccn1

InChI

InChI=1S/C17H22N2O/c1-17(20-14-13-19(2)3,15-9-5-4-6-10-15)16-11-7-8-12-18-16/h4-12H,13-14H2,1-3H3

Molecular Formula

C17H22N2O

HBD / HBA

- / 3

Ligações Rotacionáveis

6

Átomos Pesados

20

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Perguntas frequentes

An antihistamine with sedating properties used to treat insomnia and, in combination with pyridoxine, to treat nausea and vomiting during pregnancy. It works by blocking histamine receptors in the brain.

Competitively blocks histamine H1 receptors on effector cells, preventing histamine-mediated vasodilation, increased vascular permeability, bronchoconstriction, and pruritus. First-generation agents also cross the blood-brain barrier, causing sedation.

Yes, Doxylamine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1004. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 3162. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Aviso Médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.